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IMPACT ON WORK PRODUCTIVITY OF UPPER
GASTROINTESTINAL SYMPTOMS ASSOCIATED
WITH CHRONIC NSAID THERAPY IN A
SWEDISH STUDY POPULATION
Wahlqvist P, Bergenheim K, Långström G, Naesdal J
AstraZeneca R&D Mölndal, Mölndal, Sweden
OBJECTIVES: To explore the impact of upper gastroin-
testinal (GI) symptoms, deﬁned as upper abdominal pain,
discomfort or burning, in chronic NSAID users on their
ability to work and carry out daily activities. METHODS:
A productivity questionnaire was administered to
Swedish patients (n = 77) participating in an international
placebo-controlled clinical study (n = 556) on the efﬁcacy
of 4 weeks of esomeprazole treatment in a non-ulcer pop-
ulation with upper GI symptoms associated with con-
tinuous NSAID use. Productivity measures included
disease-speciﬁc absence from work, reduced productivity
while at work, and reduced productivity while carrying
out regular daily activities during the preceding week.
Responders and non-responders (irrespective of treat-
ment) were identiﬁed by use of symptom diaries (primary
measure in clinical study). RESULTS: Evaluable produc-
tivity data were obtained from 61 patients (41 respon-
ders; 20 non-responders), of which 44% (27: 14
responders; 13 non-responders) were employed. Before
start of treatment, patients reported an average of 0.4
hours absence from work per week, 13% reduced work
productivity and 26% reduced productivity in activities.
The mean difference between responders and non-
responders after treatment was 0.7 hours (p = 0.18) for
absence from work, 12% units (p < 0.05) for reduced
work productivity and 16% units (p < 0.01) for reduced
productivity in activities. On a weekly basis, results thus
imply that treatment success is associated with an avoided
loss of work productivity of 4.6 hours per patient
employed, of which 3.9 hours are due to reduced work
productivity (% reduced productivity ¥ hours worked).
Further, high and statistically signiﬁcant change score cor-
relations between symptoms, disease-speciﬁc quality of
life dimensions and reduced productivity measurements
were found, lending support to validity of these mea-
surements. CONCLUSIONS: Despite the relatively small
population sample, results indicate that successful treat-
ment of upper GI symptoms in chronic NSAID users has
a signiﬁcantly positive impact on their ability to work and
carry out daily activities.
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PMH1
METHYLPHENIDATE FORMULATION IS
ASSOCIATED WITH ACCIDENT/INJURY RATE IN
CHILDREN WITH ADHD
Lage M1, Hwang P2
1HealthMetrics Outcomes Research, Groton, CT, USA;
2Janssen-Ortho Inc,Toronto, ON, Canada
OBJECTIVE: One recommended target outcome of
ADHD therapy is enhanced safety in the community. This
study was designed to evaluate whether once-daily CON-
CERTA® extended-release (XR) methylphenidate (MPH)
is associated with a lower accident/injury rate over a 
one-year period than three-times daily (TID) immediate-
release (IR) MPH in children with attention deﬁcit/ hyper-
activity disorder (ADHD). METHODS: Data for this
analysis were derived from the IHCIS National Managed
Care Benchmark Database. Criteria for inclusion in the
analysis were: 1) age 6–12 years at date of ﬁrst prescrip-
tion for XR MPH or TID IR MPH (index date); 2)
patient-level data ﬁles containing information for at least
6 months before and 12 months after the index date; 3)
no ADHD medications in the 6-month period before the
index date; 4) no XR MPH use by the IR MPH group in
the 12-month follow-up period. The outcome variable
was the number of children with either an outpatient or
hospital claim related to an accident or injury. Multi-
variate regression analysis was performed to assess the
inﬂuence of selected demographic and clinical variables
on accident/injury rate. RESULTS: IR MPH: n = 344,
mean age 9.6 years, 76% male; XR MPH: n = 1431, mean
age 9.8 years, 75% male. XR MPH patients were less
likely (p < 0.0001) to discontinue medication (47.45% vs.
70.93%), less likely to switch to another ADHD medica-
tion (37.32% vs. 57.27%), and more likely to persist (i.e.
no gaps >14 days between prescription ﬁlls) with treat-
ment (11.67% vs. 1.74%). Children initially receiving XR
MPH were less likely to experience an accident/injury in
the 12-month follow-up period compared to those receiv-
ing IR MPH (OR = 0.58, 95% CI 0.353–0.945). CON-
CLUSIONS: These data support the use of XR MPH 
with its simpliﬁed dosing regimen for children with
ADHD. Overall care costs, not solely drug acquisition
costs, should be considered when assessing the value of a
drug.
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EVALUATION OF ANTIDEPRESSANT
MEDICATION ADHERENCE IN A NOT FOR
PROFIT HEALTH CARE ORGANIZATION
Alison LM1, Wong SL2, Day D3
1Healthﬁrst, Inc, New York, NY, USA; 2Pﬁzer, Inc, Syosset, NY,
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The federal Agency for Health Care Policy and Research
(AHCPR) recommends 12 weeks of acute treatment 
and 4 to 9 months of continuation treatment with anti-
depressant medication in patients having a new episode
of depression. OBJECTIVE: To evaluate antidepressant
medication adherence in patients with depression.
METHODS: This was a retrospective cohort study using
a 24-month pharmacy claims database. Eligible patients
must be enrolled continuously in the health plan for at
least 12 months with at least one antidepressant pre-
scription during the study period. A washout period of
90 days was applied to the front and back end of the data-
base. This allowed elimination of bias in summary results
